CRISPR Therapeutics AG

( )
CRSP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.56%423.330.0%$6024.94m
BNTXBioNTech SE -5.62%339.010.0%$1181.48m
NVAXNovavax, Inc. -4.47%226.9279.4%$901.81m
SNSSSunesis Pharmaceuticals, Inc. -3.67%8.390.7%$586.49m
AMGNAmgen, Inc. -1.95%215.111.4%$548.49m
REGNRegeneron Pharmaceuticals, Inc. -1.69%640.892.7%$486.09m
GILDGilead Sciences, Inc. -0.91%70.961.0%$430.39m
ILMNIllumina, Inc. -2.02%438.003.5%$397.21m
TECHBio-Techne Corp. -1.04%528.824.5%$352.26m
BIIBBiogen, Inc. -0.57%298.491.7%$304.57m
VRTXVertex Pharmaceuticals, Inc. -1.40%185.671.9%$238.22m
ISEEIVERIC bio, Inc. -2.41%16.220.0%$190.09m
BGNEBeiGene Ltd. -1.15%398.501.3%$184.03m
LIFEaTyr Pharma, Inc. -0.87%10.223.2%$142.93m
EXASEXACT Sciences Corp. -2.77%105.1518.1%$131.92m

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.